Literature DB >> 9709177

Differential contribution of HLA-DR, DQ, and TAP2 alleles to systemic lupus erythematosus susceptibility in Spanish patients: role of TAP2*01 alleles in Ro autoantibody production.

J M Martín-Villa1, J Martínez-Laso, M A Moreno-Pelayo, M J Castro-Panete, N Martínez-Quiles, M Alvarez, M D de Juan, J J Gómez-Reino, A Arnaiz-Villena.   

Abstract

OBJECTIVE: To study the influence MHC class II and TAP2 alleles exert on systemic lupus erythematosus (SLE) susceptibility and on the clinical and serological manifestations of the disease, in a cohort of Spanish patients.
METHODS: HLA-DR serological typing and HLA-DQA, DQB, and TAP2 DNA sequence specific oligotyping, were carried out in 85 unrelated Spanish SLE patients and 186 healthy controls. Autoantibodies detection was carried out by indirect immunofluorescence and counter immunoelectrophoresis.
RESULTS: Total SLE group: the frequency of HLA-DR3 and HLA-DQA1*0501 is significantly increased in this group (pc < 0.005, delta = 0.34 and pc < 0.005, delta = 0.45, respectively) although the highest delta value (delta = 0.87) is obtained when the TAP2*01 alleles are considered. No DQB allele shows significant deviation from the control group. Renal damage: it mainly occurs in HLA-DR3 patients (pc < 0.0005 and delta = 0.72). HLA-DQA1*0501 (p < 0.05, delta = 0.57 and DQB1*0201 (pc NS, delta = 0.56) are weaker susceptibility factors. Ro+ (but not LA) group: this autoantibody response is associated with TAP2*01 alleles in homozygosity (p < 0.05, delta = 0.81). R0/La+ group: it has a different genetic background as HLA-DQA1*0501 (delta = 1) and HLA-DQB1*0201 (delta = 1) are the main susceptibility factors.
CONCLUSIONS: A differential association between HLA-DR, DQA1, and DQB1 alleles and SLE or its clinical and serological manifestations are found. Furthermore, the associations are different to the ones reported in other ethnic groups. Finally, TAP2*01 group of alleles are associated with the highest susceptibility to SLE (higher than HLA-DR3) and may influence Ro (but not La) autoantibodies production, whereas HLA-DQA1*0501 and DQB1*0201 mediates concomitant Ro and La productions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9709177      PMCID: PMC1752585          DOI: 10.1136/ard.57.4.214

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  22 in total

Review 1.  Genetic aspects of human lupus.

Authors:  F C Arnett
Journal:  Clin Immunol Immunopathol       Date:  1992-04

2.  Antigen processing. Transporters of delight.

Authors:  P Parham
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

3.  Specific amino acid residues in the second hypervariable region of HLA-DQA1 and DQB1 chain genes promote the Ro (SS-A)/La (SS-B) autoantibody responses.

Authors:  J D Reveille; M J Macleod; K Whittington; F C Arnett
Journal:  J Immunol       Date:  1991-06-01       Impact factor: 5.422

4.  Polymorphism in a second ABC transporter gene located within the class II region of the human major histocompatibility complex.

Authors:  S H Powis; I Mockridge; A Kelly; L A Kerr; R Glynne; U Gileadi; S Beck; J Trowsdale
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

Review 5.  Genetics of systemic lupus erythematosus.

Authors:  P H Schur
Journal:  Lupus       Date:  1995-12       Impact factor: 2.911

6.  Antibodies to Ro(SSA) and the heterogeneity of systemic lupus erythematosus.

Authors:  M Reichlin; J B Harley
Journal:  J Rheumatol Suppl       Date:  1987-06

7.  Serologic studies of monozygotic twins with systemic lupus erythematosus.

Authors:  M Reichlin; J B Harley; M D Lockshin
Journal:  Arthritis Rheum       Date:  1992-04

8.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

9.  Comparison between HLA-DRB and DQ DNA sequences and classic serological markers as type 1 (insulin-dependent) diabetes mellitus predictive risk markers in the Spanish population.

Authors:  J L Vicario; J Martinez-Laso; A Corell; J M Martin-Villa; P Morales; G Lledo; O G Segurado; D de Juan; A Arnaiz-Villena
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

10.  Immunogenetics of systemic lupus erythematosus in Spanish patients: differential HLA markers.

Authors:  J J Gómez-Reino; J Martínez-Laso; J L Vicario; E Paz-Artal; A Aragón; J M Martín-Villa; M D De Juan; P Pérez-Aciego; A Arnaiz-Villena
Journal:  Immunobiology       Date:  1991-08       Impact factor: 3.144

View more
  5 in total

1.  A Central Role for HLA-DR3 in Anti-Smith Antibody Responses and Glomerulonephritis in a Transgenic Mouse Model of Spontaneous Lupus.

Authors:  Vaidehi R Chowdhary; Chao Dai; Ashenafi Y Tilahun; Julie A Hanson; Michele K Smart; Joseph P Grande; Govindarajan Rajagopalan; Shu-Man Fu; Chella S David
Journal:  J Immunol       Date:  2015-10-16       Impact factor: 5.422

2.  Spontaneous lupus-like syndrome in HLA-DQ2 transgenic mice with a mixed genetic background.

Authors:  S Rashtak; E Marietta; S Cheng; M Camilleri; M Pittelkow; C David; J Grande; J Murray
Journal:  Lupus       Date:  2010-02-08       Impact factor: 2.911

Review 3.  Unraveling the genetics of systemic lupus erythematosus.

Authors:  John B Harley; Jennifer A Kelly; Kenneth M Kaufman
Journal:  Springer Semin Immunopathol       Date:  2006-09-22

4.  Variation in the ATP-binding cassette transporter 2 gene is a separate risk factor for systemic lupus erythematosus within the MHC.

Authors:  P S Ramos; C D Langefeld; L A Bera; P M Gaffney; J A Noble; K L Moser
Journal:  Genes Immun       Date:  2009-04-23       Impact factor: 2.676

5.  The involvement of HLA -DRB1*, DQA1*, DQB1* and complement C4A loci in diagnosing systemic lupus erythematosus among Tunisians.

Authors:  Khaled Ayed; Yousr Gorgi; Saloua Ayed-Jendoubi; Rafika Bardi
Journal:  Ann Saudi Med       Date:  2004 Jan-Feb       Impact factor: 1.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.